|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant, full length human Cdc25B protein.|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin, Frozen) (IHC (P, F))||1:50 - 1:100|
|Immunoprecipitation (IP)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
MA1-26441 detects Cdc25B from human samples.
MA1-26441 has been successfully used in immunohistochemistry (frozen and paraffin), and immunoprecipitation procedures. Formalin-fixed paraffin embedded tissues require boiling in 10mM citrate buffer (pH 6.0) prior to immunostaining.
The MA1-26441 immunogen is recombinant, full length human protein.
The activity of cyclin-dependent kinases in cell cycle is regulated by the phosphorylation status, which is controlled by the antagonistic action of wee 1 kinase and Cdc25 phosphatases. Three Cdc25 genes are present in human cells: Cdc25A, Cdc25B and Cdc25C. Cdc25A and Cdc25B are expressed throughout the cell cycle, with peak expression in G1 for Cdc25A and in both G1-S phase and G2 for Cdc25B. Cdc25C is mainly expressed in G2 phase.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes.
MA1-26441 was used in immunohistochemistry to investigate the roles of CDC25A, CDC25B and CDC25C in the pathogenesis of vulvar cancer and their prognostic values
|Wang Z,Trope CG,Flørenes VA,Suo Z,Nesland JM,Holm R||BMC cancer (10:-)||2010|